Clinical Trial Update: A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma [Phase 2]

View source ↗

Summary

This Phase 2 trial update reports a study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone for relapsed multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Decadron (Dexamethasone)
• Empliciti (elotuzumab)
• Pomalyst (pomalidomide)
• Velcade (bortezomib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING